78
Item9B. Other Information
On January27, 2014, we entered into aLetterAgreementAmendmentwithBiogen Idec, which amended the clinical
development plan for ISIS-SMN
Rx
to add a newopen-label extension study for those childrenwithSMAwhohave completed dosing
in our previous studies, to expand the dosing in thePhase 2 study in infantswithSMA, and to increase the number of patients tobe
included in thePhase 3 studies. As a result of these changes, we andBiogen Idec agreed to increase the payments that we are eligible
to receive under this collaboration.
PART III
Item10. Directors, ExecutiveOfficers andCorporateGovernance
We incorporate by reference the information requiredby this Itemwith respect to directors and theAudit Committee from the
information under the caption “ELECTIONOFDIRECTORS,” including inparticular the informationunder “Nominating,
Governance andReviewCommittee” and “Audit Committee,” contained inour definitive ProxyStatement (the “ProxyStatement”),
whichwewill file onor aboutApril 25, 2014with theSecurities andExchangeCommission in connectionwith the solicitation of
proxies for our 2014AnnualMeetingof Stockholders tobe heldon June 10, 2014.
We incorporate by reference the required information concerningourCode of Ethics from the informationunder the caption
“Code of Ethics andBusinessConduct” contained in the ProxyStatement.We have filedour Code of Ethics as an exhibit toour
Report onForm8-K filed onDecember 9, 2013. Our Code of Ethics andBusinessConduct is postedon ourwebsite at
. We intend todisclose future amendments to, orwaivers from, our Code of Ethics andBusinessConduct onour
website.
Item1, Part I of thisReport contains information concerningour executive officers.We incorporate by reference the
information required by this Item concerning compliancewithSection16(a) of theSecuritiesExchangeAct of 1934, as amended,
from the information under the caption “Section16(a) Beneficial OwnershipReportingCompliance” contained in the Proxy
Statement.
Item11. ExecutiveCompensation
We incorporate by reference the information requiredby this item to the information under the caption “EXECUTIVE
COMPENSATION,” “CompensationCommittee Interlocks and Insider Participation” and “COMPENSATIONCOMMITTEE
REPORT” contained in theProxyStatement.
Item12. SecurityOwnership ofCertainBeneficialOwners andManagement andRelatedStockholderMatters
We incorporate by reference the information requiredby this item to the information under the captions “SECURITY
OWNERSHIPOFCERTAINBENEFICIALOWNERSANDMANAGEMENT” contained in the ProxyStatement.
SecuritiesAuthorized for IssuanceUnderEquityCompensationPlans
The following table sets forth information regardingoutstandingoptions and shares reserved for future issuance under our
equity compensationplans as ofDecember 31, 2013.
PlanCategory
Number of Shares
tobe Issued
UponExercise of
OutstandingOptions
WeightedAverage
ExercisePrice of
OutstandingOptions
Number of Shares
Remaining
Available for
Future Issuance
Equity compensationplans approved by stockholders(a) ..........
7,078,280 $
12.11
5,715,176(c)
Equity compensationplans not approvedby stockholders(b) ....
630,086 $
14.84
—
Total ...........................................................................................
7,708,366 $
12.33
5,715,176
(a)
Consists of four Isis plans: 1989StockOptionPlan, Amended andRestated2002Non-EmployeeDirectors’ StockOption
Plan, 2011Equity IncentivePlan andESPP.
